A
Amy Rapkiewicz
Researcher at New York University
Publications - 46
Citations - 1737
Amy Rapkiewicz is an academic researcher from New York University. The author has contributed to research in topics: Medicine & Fine-needle aspiration. The author has an hindex of 14, co-authored 39 publications receiving 1051 citations. Previous affiliations of Amy Rapkiewicz include National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series.
Amy Rapkiewicz,Xingchen Mai,Steven E. Carsons,Stefania Pittaluga,David E. Kleiner,Jeffrey S. Berger,Sarun Thomas,Nicole Adler,David M. Charytan,Billel Gasmi,Judith S. Hochman,Harmony R. Reynolds +11 more
TL;DR: In this series of seven COVID-19 autopsies, thrombosis was a prominent feature in multiple organs, in some cases despite full anticoagulation and regardless of timing of the disease course, suggesting that thROMbosis plays a role very early in the disease process.
Journal ArticleDOI
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Luca Paoluzzi,A. Cacavio,Munir Ghesani,A. Karambelkar,Amy Rapkiewicz,Jeffrey S. Weber,Gerald Rosen +6 more
TL;DR: In this article, the authors retrospectively analyzed a cohort of patients with relapsed metastatic/unresectable sarcomas, who were treated with nivolumab provided under a patient assistance program from the manufacturer.
Journal ArticleDOI
Coronavirus disease 2019 infection and placental histopathology in women delivering at term.
Elizabeth T. Patberg,Tracy Adams,Patricia Rekawek,Sevan A. Vahanian,Meredith Akerman,Andrea Hernandez,Amy Rapkiewicz,Louis Ragolia,Genevieve Sicuranza,Martin R. Chavez,Anthony M. Vintzileos,Poonam Khullar +11 more
TL;DR: It is found that COVID-19 in term patients admitted to Labor and Delivery is associated with increased rates of placental histopathologic abnormalities, particularly fetal vascular malperfusion and villitis of unknown etiology, which appear to occur even among asymptomatic term patients.
Journal ArticleDOI
Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement
Raphael Schiffmann,Amy Rapkiewicz,Mones Abu-Asab,Markus Ries,Hasan Askari,Maria Tsokos,Martha Quezado +6 more
TL;DR: The postmortem findings of a 47-year-old man with Fabry disease, an X-linked glycolipid storage disorder, who was on enzyme replacement therapy with recombinant α-galactosidase A for more than 2 years are described, concluding that, at least in this patient, repeated infusions with α-Galactoside A over a prolonged period did not appreciably clear storage material in cells other than vascular endothelial cells.
Journal ArticleDOI
The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology.
Amy Rapkiewicz,Virginia Espina,Jo Anne Zujewski,Peter F. Lebowitz,Armando C. Filie,Julia Wulfkuhle,Kevin Camphausen,Emanuel F. Petricoin,Lance A. Liotta,Andrea Abati +9 more
TL;DR: Reverse‐phase protein microarray technology has been applied successfully to the quantitative analysis of breast, ovarian, prostate, and colorectal cancers using frozen surgical specimens.